nvro-sd.htm

 

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

____________________________

 

FORM SD

 

Specialized Disclosure Report

 

____________________________

 

NEVRO CORP.

(Exact name of registrant as specified in its charter)

 

____________________________

 

 

Delaware

 

001-36715

 

56-2568057

(State or other jurisdiction
of incorporation)

 

(Commission

File Number)

 

(IRS employer

Identification No.)

 

 

1800 Bridge Parkway, Redwood City, CA

 

94065

(Address of principal executive offices)

 

(Zip code)

 

Kashif Rashid

General Counsel

650-433-3950

____________________________

 

Check the appropriate box to indicate the rule pursuant to which this form is being filed, and provide the period to which the information in this form applies:

 

         Rule 13p-1 under the Securities Exchange Act (17 CFR 240.13p-1) for the reporting period from January 1 to December 31, 2017.

 

 

 

 


 


 

 

Section 1—Conflict Minerals Disclosure

 

Item 1.01 Conflict Minerals Disclosure and Report

 

This Specialized Disclosure Report on Form SD (“Form SD”) of Nevro Corp. (“Nevro”) is filed pursuant to Rule 13p-1 promulgated under the Securities Exchange Act of 1934 for the reporting period of January 1, 2017 to December 31, 2017.

 

A copy of Nevro’s Conflict Minerals Report is provided as Exhibit 1.01 to this Form SD and is publicly available at http://www.nevro.com/English/About-Us/Corporate-Governance/default.aspx.

 

Item 1.02 Exhibit

 

As specified in Section 2, Item 2.01 of this Form SD, Nevro is hereby filing its Conflict Minerals Report as Exhibit 1.01.

 

Section 2—Exhibit

 

The attached Exhibit 1.01, entitled “Nevro Corp. Conflict Minerals Report: For the Period from January 1, 2017 to December 31, 2017” is filed as an exhibit to this Form SD report.

 

Item 2.01 Exhibit

 

Exhibit No.

 

Description

 

 

 

 

1.01

 

Conflict Minerals Report as required by Items 1.01 and 1.02 of this Form SD.


2

 


 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the duly authorized undersigned.

 

 

NEVRO CORP.

 

 

 

 

 

 

 

 

By:

/s/ Kashif Rashid

 

Date:

May 31, 2018

 

 

 

 

 

 

Kashif Rashid

 

 

 

 

General Counsel

 

 

 

 

3